Michelle Yanez, M.B.A.
Chief Financial Officer
Michelle Yanez, MBA, joined our Company as Chief Financial Officer in June 2024. Ms. Yanez is a senior financial executive with over 25 years of experience in public and privately held biotech, pharmaceutical, and life science companies. Ms. Yanez’ experience includes a broad range of responsibilities in a highly complex and regulated market. She also brings deep corporate governance experience through her work with corporate boards, including audit, compensation, nominating & governance and finance committees. Ms. Yanez’ serves as the Chief Financial Officer of MIRA Pharmaceuticals (NASDAQ: MIRA) since April 2023, which is a publicly traded pre-clinical-stage pharmaceutical development company with neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. Ms. Yanez joined MIRA in April 2022 as a Corporate Controller. From May 2002 until its acquisition in April 2022, Ms. Yanez held various leadership positions at BioDelivery Sciences International, Inc. (NASDAQ: BDSI). In her role, she led financial offerings, managed due diligence for product acquisitions and financings and managed finance documents and filings for the tender offer, leading to the acquisition of BioDelivery Sciences in April 2022. Ms. Yanez also serves as a non-employee director of Inhibitor Therapeutics, Inc. (OTCQB: INTI), a publicly traded pharmaceutical development company focused on therapeutics for certain cancers and non-cancerous proliferation disorders, since December 2022. Ms. Yanez is also Co-Founder and Chief Financial Officer of Santander Pharma Consulting, a privately held life sciences consulting firm that provides business development and commercial strategy services to pharmaceutical, medical device, and life science companies offering guidance throughout all stages of commercial development, from inception to product launch, since February 2024.
Ms. Yanez earned her B.A. in Business Management from University South Florida and further distinguished her acumen with an MBA in Strategic Leadership from Rutgers School of Business, Cum Laude.